Shopping Cart 0
Cart Subtotal
USD 0

MabVax Therapeutics Holdings Inc (MBVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

MabVax Therapeutics Holdings Inc (MabVax Therapeutics) formerly known as Telik, Inc. is a clinical-stage biotechnology company that focuses on development of pipeline of human monoclonal antibody products for diagnosis and treatment of cancer. The company's research and development activities are focused on advancing its clinical advanced drug candidates, under the antibody and vaccine programs. The pipeline product candidates include HuMab-5B1, MVT-5873, MVT-2163 and MVT-1075. The company's vaccine programs candidates for bivalent vaccine, trivalent vaccine, pentavalent vaccine and multiple vaccines. The company has partnerships with academic institutions and also with pharmaceutical and biotechnology companies. MabVax Therapeutics is headquartered in San Diego, California, the US.

MabVax Therapeutics Holdings Inc (MBVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Telik Raises USD5 Million in Venture Financing 13

Telik Raises USD4.6 Million in Venture Financing 14

Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15

MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16

Partnerships 17

MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17

MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19

MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20

Licensing Agreements 21

Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21

Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22

MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23

Equity Offering 24

MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24

MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25

MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27

MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28

MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29

MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30

MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31

MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32

MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33

MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35

MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38

MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42

MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43

MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44

Debt Offering 45

MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45

Acquisition 46

Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46

MabVax Therapeutics Holdings Inc-Key Competitors 48

MabVax Therapeutics Holdings Inc-Key Employees 49

MabVax Therapeutics Holdings Inc-Locations And Subsidiaries 50

Head Office 50

Other Locations & Subsidiaries 50

Recent Developments 51

Strategy And Business Planning 51

Jul 24, 2017: MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives 51

Financial Announcements 52

Apr 02, 2018: MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones 52

May 24, 2017: MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results 54

Corporate Communications 55

Aug 01, 2018: MabVax Therapeutics announces board of director changes 55

Jul 05, 2018: MabVax Therapeutics Receives Nasdaq Delist Determination 56

Jun 27, 2018: MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q 57

Apr 13, 2018: MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements 58

Feb 15, 2018: MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's USD 1.00 Minimum Bid Price Maintenance Requirement 59

Legal and Regulatory 60

Sep 21, 2018: Delaware Court of Chancery grants petition fied by MabVax Therapeutics 60

Sep 11, 2018: MabVax Therapeutics files suit against Sichenzia Ross Ference, a law firm that formerly represented the company in certain corporate, securities, and securities and exchange commission matters 61

Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 62

Aug 03, 2018: Delaware Court of Chancery sets hearing date On petition filed By MabVax Therapeutics 63

Jul 27, 2018: MabVax Therapeutics Files Delaware Petition 64

Product News 65

09/13/2017: MabVax Therapeutics HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress 65

Product Approvals 66

Jan 09, 2017: MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-1075 66

Clinical Trials 67

Jun 05, 2017: MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting 67

May 25, 2017: MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting 68

Feb 23, 2017: MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer 69

Feb 13, 2017: MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 70

Other Significant Developments 71

Jan 16, 2018: MabVax Therapeutics Holdings Provides Business Strategy Update 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MabVax Therapeutics Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9

MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Telik Raises USD5 Million in Venture Financing 13

Telik Raises USD4.6 Million in Venture Financing 14

Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15

MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16

MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17

MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19

MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20

Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21

Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22

MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23

MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24

MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25

MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27

MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28

MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29

MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30

MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31

MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32

MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33

MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35

MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38

MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42

MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43

MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44

MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45

Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46

MabVax Therapeutics Holdings Inc, Key Competitors 48

MabVax Therapeutics Holdings Inc, Key Employees 49

MabVax Therapeutics Holdings Inc, Subsidiaries 50

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

MabVax Therapeutics Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

MabVax Therapeutics Holdings Inc (MabVax Therapeutics) formerly known as Telik, Inc. is a clinical-stage biotechnology company that focuses on development of pipeline of human monoclonal antibody products for diagnosis and treatment of cancer. The company's research and development activities are focused on advancing its clinical advanced drug candidates, under the antibody and vaccine programs. The pipeline product candidates include HuMab-5B1, MVT-5873, MVT-2163 and MVT-1075. The company's vaccine programs candidates for bivalent vaccine, trivalent vaccine, pentavalent vaccine and multiple vaccines. The company has partnerships with academic institutions and also with pharmaceutical and biotechnology companies. MabVax Therapeutics is headquartered in San Diego, California, the US.

MabVax Therapeutics Holdings Inc (MBVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Telik Raises USD5 Million in Venture Financing 13

Telik Raises USD4.6 Million in Venture Financing 14

Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15

MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16

Partnerships 17

MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17

MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19

MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20

Licensing Agreements 21

Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21

Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22

MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23

Equity Offering 24

MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24

MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25

MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27

MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28

MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29

MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30

MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31

MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32

MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33

MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35

MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38

MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42

MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43

MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44

Debt Offering 45

MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45

Acquisition 46

Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46

MabVax Therapeutics Holdings Inc-Key Competitors 48

MabVax Therapeutics Holdings Inc-Key Employees 49

MabVax Therapeutics Holdings Inc-Locations And Subsidiaries 50

Head Office 50

Other Locations & Subsidiaries 50

Recent Developments 51

Strategy And Business Planning 51

Jul 24, 2017: MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives 51

Financial Announcements 52

Apr 02, 2018: MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones 52

May 24, 2017: MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results 54

Corporate Communications 55

Aug 01, 2018: MabVax Therapeutics announces board of director changes 55

Jul 05, 2018: MabVax Therapeutics Receives Nasdaq Delist Determination 56

Jun 27, 2018: MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q 57

Apr 13, 2018: MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements 58

Feb 15, 2018: MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's USD 1.00 Minimum Bid Price Maintenance Requirement 59

Legal and Regulatory 60

Sep 21, 2018: Delaware Court of Chancery grants petition fied by MabVax Therapeutics 60

Sep 11, 2018: MabVax Therapeutics files suit against Sichenzia Ross Ference, a law firm that formerly represented the company in certain corporate, securities, and securities and exchange commission matters 61

Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 62

Aug 03, 2018: Delaware Court of Chancery sets hearing date On petition filed By MabVax Therapeutics 63

Jul 27, 2018: MabVax Therapeutics Files Delaware Petition 64

Product News 65

09/13/2017: MabVax Therapeutics HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress 65

Product Approvals 66

Jan 09, 2017: MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-1075 66

Clinical Trials 67

Jun 05, 2017: MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting 67

May 25, 2017: MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting 68

Feb 23, 2017: MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer 69

Feb 13, 2017: MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 70

Other Significant Developments 71

Jan 16, 2018: MabVax Therapeutics Holdings Provides Business Strategy Update 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MabVax Therapeutics Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9

MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Telik Raises USD5 Million in Venture Financing 13

Telik Raises USD4.6 Million in Venture Financing 14

Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15

MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16

MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17

MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19

MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20

Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21

Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22

MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23

MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24

MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25

MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27

MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28

MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29

MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30

MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31

MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32

MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33

MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35

MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38

MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41

MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42

MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43

MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44

MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45

Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46

MabVax Therapeutics Holdings Inc, Key Competitors 48

MabVax Therapeutics Holdings Inc, Key Employees 49

MabVax Therapeutics Holdings Inc, Subsidiaries 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

MabVax Therapeutics Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.